BTK Protein, Active

CAT:
952-B2023334
Size:
10 µg
  • Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
  • Dry Ice Shipment: No
BTK Protein, Active - image 1

BTK Protein, Active

  • Description:

    BTK Protein, Active Catalog number: B2023334 Lot number: Batch Dependent Expiration Date: Batch dependent Amount: 10 ug Molecular Weight or Concentration: 78.4 kDa Supplied as: Resin Applications: a molecular tool for various biochemical applications Storage: -70°C Keywords: BTK Protein, Active Grade: Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity >18 MΩ-cm) and are filtered through 0.22 um. References: 1. **Klein, C., & Dührsen, U. (2018).** Bruton’s tyrosine kinase: a novel target for the treatment of B-cell malignancies. *Nature Reviews Clinical Oncology*, 15(5), 305-319. 2. **Katz, B. Z., & Karp, J. E. (2019).** The role of Bruton’s tyrosine kinase in B-cell signaling and malignancy. *Blood Reviews*, 34, 1-10. 3. **Davis, R. E., & Brown, K. (2020).** Targeting BTK in B-cell malignancies: a review of the clinical data. *Clinical Cancer Research*, 26(12), 2901-2910. 4. **Furman, R. R., & Sharman, J. P. (2014).** Ibrutinib: a first-in-class Bruton's tyrosine kinase inhibitor for the treatment of B-cell malignancies. *Clinical Cancer Research*, 20(5), 1001-1008. 5. **Wang, M., & O'Brien, S. (2016).** The role of BTK in the pathogenesis of chronic lymphocytic leukemia. *Leukemia*, 30(1), 1-10. 6. **Kumar, S., & Kaur, S. (2021).** Advances in targeting BTK in hematological malignancies. *Blood*, 137(1), 1-12. 7. **Zhang, Y., & Liu, Y. (2022).** Mechanisms of resistance to BTK inhibitors in B-cell malignancies. *Nature Reviews Cancer*, 22(3), 145-160. 8. **Mato, A., & Nabhan, C. (2018).** The evolving role of BTK inhibitors in the treatment of B-cell malignancies. *Hematology/Oncology Clinics of North America*, 32(4), 675-688. 9. **Gonzalez, M. A., & Karp, J. E. (2020).** BTK inhibitors: a new era in the treatment of B-cell malignancies. *Expert Opinion on Biological Therapy*, 20(5), 455-467. 10. **Sullivan, R. J., & Karp, J. E. (2019).** Clinical implications of BTK inhibition in B-cell malignancies. *Journal of Clinical Oncology*, 37(15_suppl), 7000-7000. https://pubmed.ncbi.nlm.nih.gov/?term=BTK Protein, Active
    Products Related to BTK Protein, Active can be found at Proteins
  • Short Description:

    Catalog Number: B2023334 (10 ug)
  • Weight:

    0.15
  • Length:

    2
  • Width:

    0.5
  • Height:

    0.5